IL SB0636

Adds exemption to the Pharmacy Practice Act allowing sale and distribution of dialysate and devices for home peritoneal renal dialysis for end-stage renal disease patients under specified conditions.

Requires dialysate (containing dextrose or icodextrin) and devices to be FDA-approved or cleared and held in original sealed packaging by registered manufacturers or wholesalers.

Mandates delivery only upon receipt of a physician's prescription processed by a licensed pharmacy, with the pharmacy transmitting orders to the manufacturer or manufacturer's agent.

Permits direct delivery of dialysate and devices to patients or their designees for self-administration, or to healthcare providers and institutions for patient administration.

Requires manufacturers and agents to maintain sales and distribution records in accordance with Section 18 of the Pharmacy Practice Act; excludes other peritoneal dialysis drugs from this exemption.